Drugs / Somatropin (DNA origin)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT00748969 | Nov 2008 → Sep 2013 | mucopolysaccharidosis type 1, mucopolysaccharidosis type 2, mucopolysaccharidosis type 6 | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Somatropin (DNA origin) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00748969 ↗ |
| Modality | Protein / enzyme biologic | “human growth hormone (hGH)” NCT00748969 ↗ |
| Route | Subcutaneous | “divided into daily SC injections” NCT00748969 ↗ |